As I recall, we held back on submitting the BTD for mTNBC with brain metastasis because we wanted to see how the FDA responded to the first BTD submittal. This may be more of a question for Ohm, but I wonder if sacituzumab can penetrate the brain barrier.

Quote:

---

meaning leronlimab hasn't shown a substantial improvement over the approved SOC, sacituzumab

---